Related Experiment Video

Updated: Feb 24, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

849

[AKT Is A Therapeutic Target in Myeloproliferative Neoplasms]

Jin Yu1, Zan Huang2, Jing-Yi Fan1

  • 1Department of Pediatrics, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei Province, China.

Zhongguo Shi Yan Xue Ye Xue Za Zhi
|August 22, 2017
PubMed
Abstract

Insights

AKT inhibitors show significant therapeutic effects against myeloproliferative neoplasms (MPN). This study demonstrates that blocking AKT signaling effectively inhibits MPN cell proliferation and promotes apoptosis, improving survival rates in animal models.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Myeloproliferative neoplasms (MPN) are a group of blood cancers characterized by the overproduction of myeloid cells.
  • Constitutive activation of signaling pathways like PI3K/AKT and JAK/STAT is implicated in MPN pathogenesis.

Purpose of the Study:

  • To investigate the therapeutic potential of AKT inhibitors in MPN.
  • To elucidate the mechanism by which AKT inhibition affects MPN cell behavior and survival.

Main Methods:

  • MPN cell models were generated by inducing MPL W515L expression.
  • Western blot was used to assess signaling pathway activation.
  • Cell proliferation, apoptosis, and cell cycle were analyzed following AKT inhibitor treatment.
  • In vivo studies evaluated the effect of AKT inhibition on survival in an MPN mouse model.

Main Results:

  • MPL W515L overexpression activated PI3K/AKT and JAK/STAT pathways.
  • AKT inhibition significantly suppressed MPN cell proliferation and induced apoptosis.
  • AKT inhibition led to cell cycle arrest at the G1/G0 phase.
  • Treatment with an AKT inhibitor increased survival rates in the MPN mouse model and inhibited bone marrow progenitor cell colony formation.

Conclusions:

  • AKT signaling is a critical driver in MPN.
  • Targeting AKT represents a promising therapeutic strategy for MPN and other bone marrow proliferative disorders.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.5K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
45
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K